SCM
Sarissa Capital Management Portfolio holdings
AUM
$154M
This Quarter Return
-12.46%
1 Year Return
-6.05%
3 Year Return
-7.91%
5 Year Return
+32.47%
10 Year Return
+262.41%
AUM
$405M
AUM Growth
+$405M
(-6.8%)
Cap. Flow
+$34.5M
Cap. Flow
% of AUM
8.52%
Top 10 Holdings %
Top 10 Hldgs %
92.52%
Holding
18
New
2
Increased
3
Reduced
2
Closed
–
Top Buys
| 1 |
Pacira BioSciences
PCRX
|
$15.6M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$11.2M |
| 3 |
Esperion Therapeutics
ESPR
|
$10.6M |
| 4 |
MDCO
Medicines Co
MDCO
|
$7.79M |
| 5 |
AEGR
Aegerion Pharmaceuticals, Inc.
AEGR
|
$7.05M |
Top Sells
| 1 |
Amgen
AMGN
|
$15.2M |
| 2 |
Gyre Therapeutics
GYRE
|
$2.51M |
Sector Composition
| 1 | Healthcare | 84.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
AbbVie
ABBV
$372B
| $86M | 21.23% | 1,580,000 | – | – |
|
|
ARIA
2
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $75M | 18.53% | 12,850,000 | – | – |
|
|
MDCO
3
DELISTED
Medicines Co
MDCO
| $59.5M | 14.69% | 1,567,000 +205,100 | +15% | +$7.79M |
|
4
Quest Diagnostics
DGX
$20.3B
| $35.3M | 8.73% | 575,000 | – | – |
|
|
AEGR
5
DELISTED
Aegerion Pharmaceuticals, Inc.
AEGR
| $34.7M | 8.58% | 2,555,000 +518,171 | +25% | +$7.05M |
|
|
ITCI
6
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $25.6M | 6.33% | 640,000 +280,000 | +78% | +$11.2M |
|
7
Merck
MRK
$210B
| $19.8M | 4.88% | 400,000 | – | – |
|
|
8
Pacira BioSciences
PCRX
$1.2B
| $15.6M | 3.86% | +380,000 | New | +$15.6M |
|
|
9
Amgen
AMGN
$155B
| $12.4M | 3.07% | 90,000 -110,000 | -55% | -$15.2M |
|
|
10
Esperion Therapeutics
ESPR
$448M
| $10.6M | 2.61% | +448,000 | New | +$10.6M |
|
|
SEEL
11
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
| $9.53M | 2.35% | 6,524,505 | – | – |
|
|
RPRX
12
DELISTED
Repros Therapeutics Inc.
RPRX
| $8.41M | 2.08% | 1,132,367 | – | – |
|
|
VVUS
13
DELISTED
Vivus Inc
VVUS
| $4.22M | 1.04% | 2,573,943 | – | – |
|
|
KIN
14
DELISTED
Kindred Biosciences, Inc.
KIN
| $3.58M | 0.88% | 689,091 | – | – |
|
|
AVEO
15
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| $2.8M | 0.69% | 2,313,759 | – | – |
|
16
ANI Pharmaceuticals
ANIP
$2.03B
| $1.23M | 0.3% | 31,000 | – | – |
|
|
17
Gyre Therapeutics
GYRE
$703M
| $419K | 0.1% | 90,000 -540,000 | -86% | -$2.51M |
|
18
Carisma Therapeutics
CARM
$8.98M
| $99K | 0.02% | 41,200 | – | – |
|